Vascular risk factors | First author, reference | Population | Diagnosis criteria | Treatment arm (n, drug/daily) | Control arm (n) | Duration of follow-up (months) | Measurement instrument |
---|---|---|---|---|---|---|---|
Vascular care package | Richard et al. 2009[9] | 123 AD (with co-existent cerebrovascular disease) | NINCDS-ADRDA | 58 vascular care (aspirin, advice on smoking cessation, weight loss and exercise) | 65 placebo | 24 | IDDD, MMSE, RMBPC, measures of poor outcome |
Hypertension | Ohrui et al. 2004[10]] | 162 AD | NINCDS-ADRDA | 51 brain-penetrating ACE-I | 53 non-brain penetrating inhibitor versus 58 calcium-channel blocker | 12 | MMSE |
Kume et al. 2012[11]] | 20 AD | NINCDS-ADRDA, DSM IV | 10 telmisartan (40 to 80 mg) | 10 amlodipine (5 to 10 mg) | 6 | MMSE, ADAS-JCog, WMS-R | |
Diabetes mellitus | Watson et al. 2005[20]] | 21 mild AD | NINCDS-ADRDA | 14 rosiglitazone (4 mg) | 7 placebo | 4, 6 | Buschke Selective Reminding Test, Story Recall, SCWI, TMT, category fluency |
Hanyu et al. 2009[21]] | 26 AD | NINCDS-ADRDA | 12 pioglitazone (15, 30 mg) | 14 placebo | 6 | MMSE, IDDD, RMBPC | |
Sato et al. 2011[22]] | 42 mild AD | NINCDS-ADRDA | 21 pioglitazone (15 to 30 mg) | 21 placebo | 6 | MMSE, ADAS-JCog, WMS-R, FAB | |
Risner et al. 2006[23]] | 511 mild-to moderate probable AD | NINCDS-ADRDA | 389 rosiglitazone (2, 4 or 8 mg) | 122 placebo | 6 | ADAS-Cog, CIBIC+ | |
Gold et al. 2010[24]] | 581 AD | NINCDS-ADRDA | 331 rosiglitazone (2 or 8 mg) | 166 placebo | 6 | ADAS-Cog, CIBIC+ | |
Hypercholesterolaemia | Sparks et al. 2005[30]] | 67 AD | NINCDS-ADRDA | 32 atorvastatin (80 mg) | 31 placebo | 12 | MMSE, ADAS-Cog, CGIC |
Simons et al. 2002[31]] | 44 probable AD | NINCDS-ADRDA | 24 simvastatin (80 mg) | 20 placebo | 6.5 | MMSE, ADAS-Cog | |
Feldman et al. 2010[33]] | 640 AD | NINCDS-ADRDA | 297 atorvastatin (80 mg) | 317 placebo | 18 | MMSE, ADAS-Cog, ADCS-CGIC NPI, CDR-SB, ADFACS |